The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma

• Published in: The veterinary journal (1997) Vol. 195; no. 3; pp. 319 - 324
• Main Authors: Sato, Masahiko, Yamzaki, Jumpei, Goto-Koshino, Yuko, Takahashi, Masashi, Fujino, Yasuhito, Ohno, Koichi, Tsujimoto, Hajime
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2013
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; B-lymphocytes; chemotherapy; Dog; Dog Diseases - drug therapy; Dogs; Drug Administration Schedule; Female; genes; immunoglobulin heavy chains; Lymphoma; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - veterinary; Male; Minimal residual disease; Prognosis; quantitative polymerase chain reaction; Real-time PCR; Minimal residual disease; Prognosis; Real-time PCR; Dog; Lymphoma
• ISSN: 1090-0233; 1532-2971
• DOI: 10.1016/j.tvjl.2012.07.013

The prognostic significance of minimal residual disease (MRD) in the early phases of chemotherapy was examined in 36 dogs with multicentric high-grade B-cell lymphoma. Sequences of immunoglobulin heavy chain (IgH) gene fragments from lymphoma cells were amplified and used to design allele-specific primers and probes for real-time PCR. The dogs were treated with a 6-month modified version of the University of Wisconsin–Madison chemotherapy protocol (UW-25) and evaluated for the MRD level at weeks 6 and 11 of UW-25. Of the 31 dogs that remained on the protocol at week 11, 14 were found to be MRD negative (<10tumour cells/105 peripheral blood mononuclear cells [PBMCs]), whereas the other 17 were MRD positive (⩾10tumour cells/105 PBMCs). The progression-free survival of the dogs with MRD-negative status at week 11 (median, 337days) was significantly longer than that of the MRD-positive dogs at the same time point (median, 196days) (P=0.0002). These results indicate the clinical significance of MRD as a prognostic marker in the early phase of chemotherapy.